{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:59:06Z","timestamp":1775620746741,"version":"3.50.1"},"reference-count":47,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,12,18]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Panitumumab is a recombinant human IgG<jats:sub>2<\/jats:sub> monoclonal antibody which is used for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or following FOLFIRI (fluoropyrimidine, oxaliplatin and irinotecan) containing chemotherapy regimen. We report a case of an 83-year-old Hispanic man, non-smoker, with KRAS\/NRAS wild-type mCRC of the liver who was treated with 9 cycles of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) and cetuximab. Follow-up abdominal imaging showed progression of CRC, requiring initiation of panitumumab in addition to FOLFIRI. After 2 cycles of this combination chemotherapy, he presented with acute hypoxaemic respiratory failure. Pulmonary imaging showed new onset of interstitial lung disease (ILD). He was treated with systemic corticosteroids with marked improvement of ILD. We aim to highlight the risk of severe life-threatening ILD associated with panitumumab. Early recognition of this serious adverse event helps avoid unnecessary administration of systemic antibiotics and prevent mortality.<\/jats:p>","DOI":"10.1136\/bcr-2018-227785","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T09:55:14Z","timestamp":1549706114000},"page":"bcr-2018-227785","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-9020","authenticated-orcid":false,"given":"Kamal Naguib Makar","family":"Rezkallah","sequence":"first","affiliation":[{"name":"Internal Medicine, Presence Saint Joseph Hospital Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Internal Medicine, Presence Saint Joseph Hospital Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabah","family":"Patel","sequence":"additional","affiliation":[{"name":"Presence St Joseph Hospital, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Kozma","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Presence Saint Joseph Hospital Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"2025082710501356000_12.2.bcr-2018-227785.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1609"},{"key":"2025082710501356000_12.2.bcr-2018-227785.2","doi-asserted-by":"publisher","DOI":"10.2165\/11205090-000000000-00000"},{"key":"2025082710501356000_12.2.bcr-2018-227785.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00134-7"},{"key":"2025082710501356000_12.2.bcr-2018-227785.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.5.1168"},{"key":"2025082710501356000_12.2.bcr-2018-227785.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"2025082710501356000_12.2.bcr-2018-227785.6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-577"},{"key":"2025082710501356000_12.2.bcr-2018-227785.7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10147-015-0834-3","article-title":"Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study","volume":"20","author":"Osawa","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2025082710501356000_12.2.bcr-2018-227785.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602063"},{"key":"2025082710501356000_12.2.bcr-2018-227785.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0199-0"},{"key":"2025082710501356000_12.2.bcr-2018-227785.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj057"},{"key":"2025082710501356000_12.2.bcr-2018-227785.11","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528020-00002"},{"key":"2025082710501356000_12.2.bcr-2018-227785.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"2025082710501356000_12.2.bcr-2018-227785.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"2025082710501356000_12.2.bcr-2018-227785.14","first-page":"31","article-title":"The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis","volume":"3","author":"Stephens","year":"2010","journal-title":"Int J Gen Med"},{"key":"2025082710501356000_12.2.bcr-2018-227785.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"2025082710501356000_12.2.bcr-2018-227785.16","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0780"},{"key":"2025082710501356000_12.2.bcr-2018-227785.17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082710501356000_12.2.bcr-2018-227785.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn066"},{"key":"2025082710501356000_12.2.bcr-2018-227785.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2235"},{"key":"2025082710501356000_12.2.bcr-2018-227785.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.03.015"},{"key":"2025082710501356000_12.2.bcr-2018-227785.21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601"},{"key":"2025082710501356000_12.2.bcr-2018-227785.22","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.019"},{"key":"2025082710501356000_12.2.bcr-2018-227785.23","first-page":"31","article-title":"The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis","volume":"3","author":"Stephens","year":"2010","journal-title":"Int J Gen Med"},{"key":"2025082710501356000_12.2.bcr-2018-227785.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"2025082710501356000_12.2.bcr-2018-227785.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2354"},{"key":"2025082710501356000_12.2.bcr-2018-227785.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq061"},{"key":"2025082710501356000_12.2.bcr-2018-227785.27","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082710501356000_12.2.bcr-2018-227785.28","doi-asserted-by":"publisher","DOI":"10.1159\/000076670"},{"key":"2025082710501356000_12.2.bcr-2018-227785.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.06.103"},{"key":"2025082710501356000_12.2.bcr-2018-227785.30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.rmed.2015.10.005","article-title":"The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis","volume":"109","author":"Okamoto","year":"2015","journal-title":"Respir Med"},{"key":"2025082710501356000_12.2.bcr-2018-227785.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025082710501356000_12.2.bcr-2018-227785.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2025082710501356000_12.2.bcr-2018-227785.33","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12051010"},{"key":"2025082710501356000_12.2.bcr-2018-227785.34","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.3.9903021"},{"key":"2025082710501356000_12.2.bcr-2018-227785.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90300-1"},{"key":"2025082710501356000_12.2.bcr-2018-227785.36","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200001000-00003"},{"key":"2025082710501356000_12.2.bcr-2018-227785.37","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00158507"},{"key":"2025082710501356000_12.2.bcr-2018-227785.38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/resp.12674","article-title":"Idiopathic non-specific interstitial pneumonia","volume":"21","author":"Belloli","year":"2016","journal-title":"Respirology"},{"key":"2025082710501356000_12.2.bcr-2018-227785.39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00071004"},{"key":"2025082710501356000_12.2.bcr-2018-227785.40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2169\/internalmedicine.41.867","article-title":"Nonspecific interstitial pneumonia\/fibrosis completely recovered by adding cyclophosphamide to corticosteroids","volume":"41","author":"Nanki","year":"2002","journal-title":"Intern Med"},{"key":"2025082710501356000_12.2.bcr-2018-227785.41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00114004"},{"key":"2025082710501356000_12.2.bcr-2018-227785.42","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.1.209"},{"key":"2025082710501356000_12.2.bcr-2018-227785.43","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.1.213"},{"key":"2025082710501356000_12.2.bcr-2018-227785.44","first-page":"117","article-title":"Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis","volume":"11","author":"Al-Hameed","year":"2004","journal-title":"Can Respir J"},{"key":"2025082710501356000_12.2.bcr-2018-227785.45","first-page":"102","article-title":"Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis","volume":"11","author":"Rangappa","year":"2009","journal-title":"Crit Care Resusc"},{"key":"2025082710501356000_12.2.bcr-2018-227785.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.06.003"},{"key":"2025082710501356000_12.2.bcr-2018-227785.47","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3332\/ecancer.2018.841","article-title":"Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen","volume":"12","author":"Al-Asadi","year":"2018","journal-title":"Ecancermedicalscience"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:50:21Z","timestamp":1756317021000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,9]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bcr-2018-227785"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227785","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}